about
Mapping the active site polarity in structures of endothelial nitric oxide synthase heme domain complexed with isothioureasDesign of HIV protease inhibitors based on inorganic polyhedral metallacarboranesCrystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal centerPotentiometric response and mechanism of anionic recognition of heterocalixarene-based ion selective electrodesFormation of lanthanide(III) texaphyrin complexes with DNA controlled by the size of the central metal cation.Water soluble sapphyrins: potential fluorescent phosphate anion sensors.Anion-controlled assembly of porphyrin-bicyclic guanidine conjugates.Overcoming regioselectivity issues inherent in bis-Tröger's base preparation.Steroid-porphyrin conjugate for saccharide sensing in protic media.Cytosine substituted calix[4]pyrroles: neutral receptors for 5'-guanosine monophosphateFrom nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV proteaseLow-melting salts based on a glycolated cobalt bis(dicarbollide) anion.Nitric oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors.Lanthanide complexes as fluorescent indicators for neutral sugars and cancer biomarkers.A supramolecular approach to protein labeling. A novel fluorescent bioassay for concanavalin a activityTherapeutic application of peptides and proteins: parenteral forever?Application of gold nanoparticles in separation sciences.Selective recognition of a saccharide-type tumor marker with natural and synthetic ligands: a new trend in cancer diagnosis.Oligo Tröger's bases--new molecular scaffolds.Application of cyclodextrins in chiral capillary electrophoresis.Polyhydroxylated sapphyrins: multisite non-metallic catalysts for activated phosphodiester hydrolysis.Caffeine-hydrazones as anticancer agents with pronounced selectivity toward T-lymphoblastic leukaemia cells.Striking antitumor activity of a methinium system with incorporated quinoxaline unit obtained by spontaneous cyclization.Polytetrafluorethylene-Au as a substrate for surface-enhanced Raman spectroscopy.Rational design of chemical ligands for selective mitochondrial targeting.New polyfluorothiopropanoyloxy derivatives of 5β-cholan-24-oic acid designed as drug absorption modifiers.Optical probes and sensors as perspective tools in epigenetics.New propanoyloxy derivatives of 5β-cholan-24-oic acid as drug absorption modifiers.Temoporfin-loaded 1-tetradecanol-based thermoresponsive solid lipid nanoparticles for photodynamic therapy.Combination of two chromophores: synthesis and PDT application of porphyrin-pentamethinium conjugate.Investigation of new acyloxy derivatives of cholic acid and their esters as drug absorption modifiers.Modified porphyrin-brucine conjugated to gold nanoparticles and their application in photodynamic therapy.Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells.Porphyrin-bile acid conjugates: from saccharide recognition in the solution to the selective cancer cell fluorescence detection.p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivative.Influence of substituent position and cavity size of the regioisomers of monocarboxymethyl-α-, β-, and γ-cyclodextrins on the apparent stability constants of their complexes with both enantiomers of Tröger's base.Biodistribution assessment of a lutetium(III) texaphyrin analogue in tumor-bearing mice using NIR Fourier-transform Raman spectroscopy.Novel cationic transport agents for oligonucleotide delivery into primary leukemic cells.Gold and silver nanoparticles for biomolecule immobilization and enzymatic catalysis.Chiral switch of enzymatic ketone reduction by addition of gamma-cyclodextrin.
P50
Q27627674-2DF1F258-5A54-40B1-B94A-B975A489586DQ27658013-DEE5B591-C937-4BA2-B8EA-8DAEFA7781A8Q27766420-3BE49795-A420-459C-A312-EDD5279DC599Q28221488-4965DED2-A5C0-48BD-B2E9-7D4E3ADD60D1Q30788914-C9F478B0-2EE0-4E1D-958D-C456759D869CQ30885814-912C62BE-90F1-4515-9518-70DCC1BBC07CQ31033835-321B7962-C9CD-41D1-9432-86D7E47FA7ADQ31064389-BEC68EFA-EF6C-453E-82B5-E5335C9FEEA6Q33194321-D780EC8E-6BCC-4D83-B7D4-E028EE342F3AQ34022345-C9534948-97A2-4652-837E-EFD812C873D1Q34081415-A092D9AC-ADDA-459E-9EF2-FF6378EDBB65Q34203162-307B600A-EC91-4753-B78E-0D863B65761BQ34449706-267A7302-0948-4E9F-B46E-4B8C767B2F2DQ34684426-FD435213-E00C-4CFB-909C-447C603427A3Q36063060-498DDA35-AEB9-4F80-8ACA-1EB5C32E2F26Q37600236-2002B21F-4588-4BC9-9E5F-FD4BD75BB289Q37680794-23396635-D909-4D3D-A0FE-A2BCE8EBCA4BQ37785832-C2159620-C49E-4212-A22F-14E8668A7AF7Q37996284-34B99C5C-B93B-4333-B4EF-7EB2A7C1C8B7Q38213942-31753196-35FB-4A30-97ED-437A14E878ABQ38316960-9F6E6FE8-5941-4118-AC52-6D00B8E04EB9Q38882375-830490A6-68BC-484F-BFEA-108591C07D33Q38915632-B0AE032B-A05D-4541-8CA4-8F3970C6505CQ38995530-C5532147-C8CA-4C2F-9702-741DDD6DD47CQ39107812-52B0F088-2495-40CF-9B2F-DBD71D31B4B3Q39147548-C101FA63-40B5-4B91-AA55-167F016DEAFDQ39175017-788D28F7-9B98-47AA-95C0-AA8DBBFF8C9CQ39189719-26FF6EF9-7EA1-4222-A7A5-D7EE2651E27AQ39396612-098A6602-FBEF-4BAD-A58A-9AF8B2D9F5E9Q39431175-C6017743-1C54-4AA6-8133-F94128333246Q39545213-D779FEC5-0239-473C-AFE1-417282788F15Q39702162-454BADF3-5E48-4F87-9AC0-DA58E3062922Q39940540-E8C88EEB-ED07-49C6-A27A-C09165F0B599Q39990823-A2D2EE46-78A1-45F0-8A7E-D8A903BEBD83Q40039733-440F1EB1-091E-4171-BB93-62427CE4A2F4Q40179973-EC52E833-6CE9-4643-990E-FD4B0EB72419Q40546929-5D837145-A667-4D18-9028-CBE4477CC2C5Q40647824-18786990-02D5-40B5-B536-DF8873008A85Q42326619-97F5ACD2-C29E-43FF-AA53-8683ADA8A743Q42924734-05423A0D-0FA8-4F6C-81F1-CB6B20F2220B
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
výzkumník v oblasti medicinální chemie, manažer Zentivy a akademik
@cs
wetenschapper
@nl
հետազոտող
@hy
name
Vladimir Kral
@sq
Vladimír Král
@ast
Vladimír Král
@cs
Vladimír Král
@de
Vladimír Král
@en
Vladimír Král
@es
Vladimír Král
@nl
Vladimír Král
@sk
Vladimír Král
@sl
type
label
Vladimir Kral
@sq
Vladimír Král
@ast
Vladimír Král
@cs
Vladimír Král
@de
Vladimír Král
@en
Vladimír Král
@es
Vladimír Král
@nl
Vladimír Král
@sk
Vladimír Král
@sl
prefLabel
Vladimir Kral
@sq
Vladimír Král
@ast
Vladimír Král
@cs
Vladimír Král
@de
Vladimír Král
@en
Vladimír Král
@es
Vladimír Král
@nl
Vladimír Král
@sk
Vladimír Král
@sl
P106
P214
P1053
I-9518-2017
P1153
7101993492
P19
P21
P214
P31
P3829
P496
0000-0001-5034-4184
P569
1949-12-26T00:00:00Z
P570
2019-04-01T00:00:00Z
P691
jo20010088887
P734
P735
P7859
viaf-84128072